Bringing a new therapy to market takes years and costs billions, leaving biopharma under increasing pressure to compress development timelines. Overcoming that inertia requires rethinking traditional approaches to identifying biomarkers, generating evidence, and scaling trials, which remain slow and fragmented. Pathology—long the foundation of diagnosis—is emerging as a critical and underutilized source of data and insight that can fuel every stage of therapeutic development and delivery.
In this GEN webinar, Nathan Buchbinder and Ritida Nanda will discuss how Proscia Aperture™, powered by the Concentriq® enterprise pathology platform and global network of diagnostic labs, transforms routine clinical data into a real-time intelligence engine for biopharma. During the webinar, you will learn how Aperture connects multimodal pathology data, specifically whole slide tissue images, molecular test results, and clinical context, across a global diagnostic network. They will also discuss how pathology data captured and analyzed at diagnosis can reveal novel biomarkers and validate targets, accelerate patient recruitment and optimize trial design, generate real-world evidence that reflects true patient diversity and disease progression, and support collaboration between diagnostic labs and biopharma. By attending this webinar, you will:
- Understand how pathology data expands biopharma’s precision medicine toolbox with real-time diagnostic signals.
- See practical use cases for digital pathology and AI across the drug development continuum—from discovery to commercialization.
- Learn how a global network of diagnostic labs can support scalable, patient-centric trial recruitment and real-world evidence generation.
- Gain insights from experts on how pathology intelligence is transforming biopharma’s approach to discovery, development, and access.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
